WCN26-6772 A WORLD OF DATA TO ADVANCE KIDNEY CARE: APOLLODIALDB 2.0

20260 citationsJournal Articlegold Open Access

Authors

Yue Jiao · Renal Research Institute

Melanie Wolf · Renal Research Institute

Kaitlyn Croft · Renal Research Institute

Justin Zimbelman · Renal Research Institute

Kanti Singh · Fresenius Medical Care (United States)

Milind Nikam · Fresenius Medical Care (United States)

Adrián Guinsburg

Abstract

Conclusion:In this 36-week, phase III trial comparing maintenance therapy with rESP administered intravenously every other week with rhEPO administered intravenously one to three times weekly, rESP was noninferior to rhEPO for the treatment of anemia in patients with chronic renal failure undergoing hemodialysis, with comparable safety profiles.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Topics & Keywords

Heart Failure Treatment and Management Electronic Health Records Systems Chronic Disease Management Strategies

UN Sustainable Development Goals

Gender equality

Publication Details

Published in: Kidney International Reports

Volume 11, Issue 4, pp. 104868-104868

DOI: 10.1016/j.ekir.2026.104868

Field-Weighted Citation Impact: 0.00